Can progesterone stop or reduce menstrual bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Progesterone Stop Menstrual Bleeding?

Yes, progesterone can effectively reduce and stop menstrual bleeding, with the levonorgestrel-releasing intrauterine device (LNG-IUS) being the most effective option (reducing menstrual blood loss by 71-95%), while oral cyclic progestins reduce bleeding by approximately 87%, though they are less effective than the LNG-IUS. 1

Most Effective Progesterone-Based Options

Levonorgestrel-Releasing Intrauterine Device (LNG-IUS)

  • The LNG-IUS (20 μg/day) is the single most effective progesterone-based treatment for heavy menstrual bleeding, achieving 71-95% reduction in menstrual blood loss 1
  • This is the only progestin intrauterine device that has been formally evaluated for treatment of abnormal uterine bleeding 1
  • Efficacy is comparable to endometrial ablation procedures 1
  • Works primarily at the endometrial level with minimal systemic progesterone absorption 1
  • 22% of users experience complete amenorrhea (cessation of bleeding) 1

Oral Cyclic Progestin Treatment

  • Cyclic oral progestin reduces bleeding by 87% and typically results in irregular bleeding with eventual reduction to light bleeding only 1
  • Standard dosing for secondary amenorrhea: 400 mg progesterone capsules daily at bedtime for 10 days 2
  • For endometrial protection in postmenopausal women on estrogen: 200 mg progesterone capsules daily at bedtime for 12 continuous days per 28-day cycle 2
  • Recent evidence shows adding 5 mg norethisterone acetate to progesterone-only pills significantly reduces breakthrough bleeding after 2,4, and 6 weeks 3

Comparative Effectiveness

Oral Progestins vs. Other Medical Therapies

  • Short-cycle progestins (7-10 days during luteal phase) are inferior to tranexamic acid, danazol, and the LNG-IUS for reducing menstrual blood loss 4
  • Long-cycle progestins (day 5-26 of cycle) are also inferior to LNG-IUS, tranexamic acid, and ormeloxifene 4
  • However, oral progestins may be similar in effectiveness to combined vaginal ring therapy 4

LNG-IUS vs. Surgical Options

  • The LNG-IUS is more effective than oral medications but less effective than hysterectomy for complete bleeding control 5
  • When compared to endometrial ablation, the LNG-IUS shows similar satisfaction rates and quality of life improvements, though evidence quality is low 5
  • The LNG-IUS is more cost-effective than both endometrial ablation (within 2 years) and hysterectomy (up to 10 years) 5

Clinical Application Algorithm

For Acute Heavy Menstrual Bleeding

  • High-dose oral or injectable progestin-only medications may be considered short-term in hemodynamically unstable women when bleeding is not controlled 1
  • Rule out pregnancy first in all reproductive-age women with abnormal bleeding 1
  • Assess for hemodynamic instability (bleeding saturating large pad/tampon hourly for ≥4 hours warrants urgent evaluation) 1

For Chronic Heavy Menstrual Bleeding

  1. First-line: Consider LNG-IUS for maximum effectiveness (71-95% reduction) 1, 6
  2. Second-line: Cyclic oral progestins if LNG-IUS is unacceptable or contraindicated (87% reduction) 1, 6
  3. For breakthrough bleeding on progesterone-only pills: Add norethisterone acetate 5 mg 3

For Secondary Amenorrhea (Inducing Withdrawal Bleeding)

  • Progesterone capsules 400 mg daily at bedtime for 10 days results in 80% of women experiencing withdrawal bleeding within 7 days 2
  • Alternative dosing: 300 mg daily for 10 days achieves 73.8% withdrawal bleeding rate 2

Important Caveats and Contraindications

Special Population: Women with Cardiovascular Disease

  • In women with spontaneous coronary artery dissection (SCAD), hormonal therapy including progesterone is relatively contraindicated and requires careful clinical judgment 1
  • The LNG-IUS may still be considered in SCAD patients due to minimal systemic absorption, though theoretical safety concerns exist 1
  • Hormone replacement therapy should not be used for secondary prevention in women with established coronary artery disease 7

Common Side Effects

  • Minor adverse effects are more common with LNG-IUS: pelvic pain, breast tenderness, ovarian cysts, and intermenstrual bleeding/spotting (especially first 3-6 months) 5
  • Oral progesterone capsules may cause drowsiness, dizziness, blurred vision, difficulty speaking, or difficulty walking—should be taken at bedtime in standing position with water 2
  • Unscheduled bleeding or amenorrhea with progestin therapy is generally not harmful 1

Absolute Contraindications to Progesterone

  • Allergy to peanuts (progesterone capsules contain peanut oil) 2
  • Current unusual vaginal bleeding of unknown cause 2
  • Current or history of certain cancers (breast, uterus) 2
  • Active or history of blood clots, stroke, or heart attack 2
  • Current liver problems 2
  • Pregnancy 2

Counseling Points

  • Enhanced counseling about expected bleeding patterns reduces discontinuation rates 1, 6
  • With LNG-IUS: 22% experience amenorrhea, 34% infrequent spotting, but 7% have frequent bleeding and 18% prolonged bleeding 1
  • Reassure patients that irregular bleeding patterns are generally not harmful 1, 6
  • If bleeding persists despite treatment and is unacceptable to the patient, counsel on alternative methods 1, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cyclical progestogens for heavy menstrual bleeding.

The Cochrane database of systematic reviews, 2019

Guideline

Management of Abnormal Uterine Bleeding with Progestin-Only Contraceptives

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Progesterone Therapy in Patients with Coronary Artery Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.